Both in Pharmaceuticals
Erasca vs PTC Therapeutics
Over the past year ERAS returned +545.5% and PTCT returned +1.8%; their daily moves had a correlation of 0.10.
ERAS +545.5% PTCT +1.8%Growth of $1, one year, split-adjusted
| Metric | ERAS | PTCT |
|---|---|---|
| Price | $14.91 | $68.97 |
| Market cap | $5.21B | $5.76B |
| Today | +1.84% | +1.25% |
| 1 month | +4.3% | +8.3% |
| 6 months | +36.8% | +3.6% |
| Year to date | +300.8% | −9.2% |
| 1 year | +526.5% | +1.5% |
| Revenue growth (YoY) | — | +69.6% |
| Gross margin | — | 93.4% |
| Net margin | — | −14.4% |
| P/E (TTM) | — | — |
| Price / sales | — | 5.0× |
| Net cash | $268.7M | $1.59B |
| Dividend yield | — | — |
| Volatility (60d) | 59.7% | 43.5% |
| Short % of float | 14.5% | 10.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).